- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00561015
A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection
7 czerwca 2013 zaktualizowane przez: Tibotec BVBA
A Phase IIa Randomized, Partially Blinded Trial of Telaprevir (VX-950) in Treatment-Naive Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection
The purpose of this study is to assess the effect of telaprevir on early hepatitis (inflammation of the liver) C virus (HCV) viral kinetics in treatment-naive participants who are chronically (lasting a long time) infected with genotype 2 or 3 HCV.
Przegląd badań
Status
Zakończony
Interwencja / Leczenie
Szczegółowy opis
This is a Phase 2a multicenter (when more than one hospital or medical school team work on a medical research study), partially blinded, randomized (study drug assigned by chance) stratified (arrange in groups for analysis of results e.g., stratify by age, sex, etc.) for genotype, multiple dose study.
The trial will consist of Screening period (6 weeks), Treatment period (24 or 26 weeks) and Follow-up period (24 weeks).
The Treatment period will include 2 weeks investigational treatment phase and a 24 week standard treatment phase.
All the eligible participants who were never treated for HCV will be enrolled for the trial and will receive the investigational treatment regimen to which they have been randomly assigned for 2 weeks.
After this in the standard treatment phase participants will receive the standard treatment of care consisting of pegylated interferon (Peg-IFN)-alfa-2a 180 microgram once weekly and ribavirin (RBV) 400 milligram twice per day.
Efficacy will primarily be evaluated by HCV viral load quantification.
Participant's safety will be monitored throughout the study.
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
52
Faza
- Faza 2
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
-
Clichy, Francja
-
Creteil N/A, Francja
-
Lyon, Francja
-
Paris, Francja
-
Vandoeuvre Les Nancy, Francja
-
-
-
-
-
Stockholm, Szwecja
-
-
-
-
-
London, Zjednoczone Królestwo
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat do 65 lat (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Wszystko
Opis
Inclusion Criteria:
- Participants chronically infected with genotype 2 or 3 hepatitis C virus (HCV) with amount of virus in the blood greater than 10,000 international units per milliliter (IU/ml)
- Participants who were never treated for hepatitis C virus infection
- Participants without any significant lab abnormalities
- Participants who agree to the use of two effective methods of contraception
- Participant who were judged to be in good health
Exclusion Criteria:
- Participants who had contraindications for starting anti-HCV therapy
- Participants who had history or evidence of liver cirrhosis (serious liver disorder in which connective tissue replaces normal liver tissue, and liver failure often occurs) or decompensated liver disease or hepatocellular carcinoma (type of cancer)
- Participant infected with human immunodeficiency virus (a life-threatening infection that you can get from an infected person's blood or from having sex with an infected person) or hepatitis B virus
- Females who are pregnant (carrying an unborn baby), planning to be pregnant or breastfeeding
- Participants who have hypersensitivity to tartrazine
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: TVR then Peg-IFN-alfa-2a + RBV (T2 & PR24) - Genotype 2
Participants who are never treated for chronic hepatitis C (inflammation of the liver) genotype 2 will receive telaprevir (TVR) 750 milligram (mg) tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15.
Participants will then be treated with standard treatment regimen of pegylated interferon (Peg-IFN)-alfa-2a and ribavirin (RBV) from Day 15 to Week 26 (standard treatment phase).
Each dose of pegylated interferon 180 microgram (mcg) will be administered as a subcutaneous injection once a week.
RBV will be taken orally as 400 mg tablets 2 times a day.
Total duration of treatment will be 26 weeks.
|
Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.
Inne nazwy:
Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 & PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
|
Eksperymentalny: TVR with Peg-IFN-alfa-2a + RBV (T2/PR24) - Genotype 2
Participants who are never treated for CHC genotype 2 will receive TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24.
Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week.
RBV will be taken orally as 400 mg tablets 2 times a day.
Total duration of treatment will be 24 weeks.
|
Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.
Inne nazwy:
Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 & PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
|
Aktywny komparator: Pbo with Peg-IFN-alfa-2a + RBV (Pbo/PR24) - Genotype 2
Participants who are never treated for CHC genotype 2 will receive TVR matching placebo (Pbo) tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24.
Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week.
RBV will be taken orally as 400 mg tablets 2 times a day.
Total duration of treatment will be 24 weeks.
|
Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 & PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks.
|
Eksperymentalny: TVR then Peg-IFN-alfa-2a + RBV (T2 & PR24) - Genotype 3
Participants who are never treated for CHC genotype 3 will receive TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15.
Participants will then be treated with standard treatment regimen of Peg-IFN-alfa-2a and RBV from Day 15 to Week 26 (standard treatment phase).
Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week.
RBV will be taken orally as 400 mg tablets 2 times a day.
Total duration of treatment will be 26 weeks.
|
Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.
Inne nazwy:
Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 & PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
|
Eksperymentalny: TVR with Peg-IFN-alfa-2a + RBV (T2/PR24) - Genotype 3
Participants who are never treated for CHC genotype 3 received TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24.
Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week.
RBV will be taken orally as 400 mg tablets 2 times a day.
Total duration of treatment will be 24 weeks.
|
Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.
Inne nazwy:
Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 & PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
|
Aktywny komparator: Pbo with Peg-IFN-alfa-2a + RBV (Pbo/PR24) - Genotype 3
Participants who are never treated for CHC genotype 3 will receive TVR matching Pbo tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24.
Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week.
RBV will be taken orally as 400 mg tablets 2 times a day.
Total duration of treatment will be 24 weeks.
|
Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 & PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level at Day 15
Ramy czasowe: Baseline, Pre-dose (Day 15)
|
Level of HCV RNA in plasma was measured using COBAS TaqMan HCV test v2.0 (an in vitro nucleic acid amplification test for quantitation of HCV RNA genotypes 1 through 6 in human serum or plasma, using the COBAS AmpliPrep Total Nucleic Acid Isolation Kit (TNAI) for preparation of highly purified total nucleic acid from serum or plasma and automated amplification and detection on TaqMan 48 Analyzer).
Lower limit of quantification was 25 international units/milliliter (IU/ml) and limit of detection was 10 IU/ml.
Assay used was reverse transcription-polymerase chain reaction (RT-PCR) methodology.
|
Baseline, Pre-dose (Day 15)
|
Maximum Plasma Concentration (Cmax) for Telaprevir on Day 1
Ramy czasowe: Pre-dose Day 1 (0.5, 1, 2, 3, 4, 6, 8 hour [hr])
|
The Cmax is defined as the maximum observed analyte concentration.
The Cmax was measured in nanogram/milliliter (ng/ml).
|
Pre-dose Day 1 (0.5, 1, 2, 3, 4, 6, 8 hour [hr])
|
Time to Reach Maximum Plasma Concentration (Tmax) for Telaprevir on Day 1
Ramy czasowe: Pre-dose Day 1 (0.5, 1, 2, 3, 4, 6, 8 hr)
|
The Tmax is defined as the actual sampling time to reach maximum observed analyte concentration.
The analyte concentration associated with Tmax is referred to as Cmax.
|
Pre-dose Day 1 (0.5, 1, 2, 3, 4, 6, 8 hr)
|
Area Under Plasma Concentration-Time Curve Over Dosing Interval (AUCtau) for Telaprevir on Day 1
Ramy czasowe: Pre-dose Day 1 (0.5, 1, 2, 3, 4, 6, 8 hr)
|
The AUC is defined as area under the plasma concentration-time curve over the dosing interval (8 hr), calculated by the lin-up/ log-down method.
|
Pre-dose Day 1 (0.5, 1, 2, 3, 4, 6, 8 hr)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Area Under Plasma Concentration-Time Curve Over Dosing Interval (AUCtau) for Telaprevir on Day 15
Ramy czasowe: Pre-dose Day 15 (0.5, 1, 2, 3, 4, 6, 8 hr)
|
The AUC is defined as area under the plasma concentration-time curve over the dosing interval (8 hr), calculated by the lin-up/ log-down method.
|
Pre-dose Day 15 (0.5, 1, 2, 3, 4, 6, 8 hr)
|
Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level at Week 24 and Week 26
Ramy czasowe: Baseline and Week 24/26
|
Levels of HCV RNA in plasma were measured using COBAS TaqMan HCV test v2.0.
Lower limit of quantification was 25 IU/ml and limit of detection was 10 IU/ml.
The assay used real time RT-PCR methodology.
End of treatment (EOT) for group T2 & PR24 was 26 weeks and for groups T2/PR24 and Pbo/PR24 was 24 weeks.
|
Baseline and Week 24/26
|
Maximum Plasma Concentration (Cmax) for Telaprevir on Day 15
Ramy czasowe: Pre-dose Day 15 (0.5, 1, 2, 3, 4, 6, 8 hr)
|
The Cmax is defined as the maximum observed analyte concentration.
The Cmax is measured in ng/ml.
|
Pre-dose Day 15 (0.5, 1, 2, 3, 4, 6, 8 hr)
|
Minimum Plasma Concentration (Cmin) for Telaprevir on Day 15
Ramy czasowe: Pre-dose Day 15 (0.5, 1, 2, 3, 4, 6, 8 hr)
|
The Cmin is defined as minimum plasma concentration between 0 hr and dosing interval.
The Cmin is measured in ng/ml.
|
Pre-dose Day 15 (0.5, 1, 2, 3, 4, 6, 8 hr)
|
Percentage of Participants Achieving Virological Response (HCV RNA Level < 10 IU/ml)
Ramy czasowe: Baseline, Day 12, 15, Week 4, 6, 14 and EOT (Week 24/26 or early discontinuation)
|
Virological response was defined as having HCV RNA level less than a particular threshold that is less than 10 IU/ml (undetectable).
|
Baseline, Day 12, 15, Week 4, 6, 14 and EOT (Week 24/26 or early discontinuation)
|
Median Time to Virological Response (HCV RNA Level < 10 IU/ml)
Ramy czasowe: Baseline up to EOT
|
Virological response was defined as having HCV RNA level less than a particular threshold which is either less than 10 IU/ml (undetectable) or less than 25 IU/ml (unquantifiable).Time to virological response was defined as the number of days from the start of medication intake necessary to go for the first time below the threshold value.
The EOT for group T2 & PR24 was 26 weeks and for groups T2/PR24 and Pbo/PR24 was 24 weeks.
|
Baseline up to EOT
|
Percentage of Participants With Viral Breakthrough
Ramy czasowe: Baseline, Day 12, 15 and Week 24/26
|
Viral breakthrough was defined as an increase in HCV RNA levels by more than 1 log10 in HCV RNA level from the lowest level reached, or a value of HCV RNA > 100 IU/ml in participants whose HCV RNA had previously become undetectable (< 10 IU/ml) or unquantifiable (< 25 IU/ml) during the considered treatment phase.
It was considered as confirmed when the criterion for viral breakthrough is fulfilled at two or more consecutive time points or at the last observed time point in case of trial termination.
The EOT for group T2 & PR24 was 26 weeks and for groups T2/PR24 and Pbo/PR24 was 24 weeks.
|
Baseline, Day 12, 15 and Week 24/26
|
Percentage of Participants Who Demonstrated Virological Relapse
Ramy czasowe: 24 weeks after EOT
|
Relapse was defined as confirmed detectable HCV RNA (>=10 IU/ml) during the follow-up period up to 24 weeks after last medication intake and after previous undetectable HCV RNA (< 10 IU/ml) at EOT.
No relapse was defined as having no confirmed detectable HCV RNA (>=10 IU/ml) during the follow-up period and after previous undetectable HCV RNA (< 10 IU/ml) at EOT. Missing follow-up means no HCV RNA measurements during the follow-up period and after previous undetectable HCV RNA (< 10 IU/ml) at EOT.
The EOT for group T2 & PR24 was 26 weeks and for groups T2/PR24 and Pbo/PR24 was 24 weeks.
|
24 weeks after EOT
|
Percentage of Participants Who Achieved Sustained Virological Response (SVR)
Ramy czasowe: Week 12, 24 after EOT
|
The SVR was defined as having HCV RNA undetectable at EOT, not showing relapse up to follow-up Week 12 (SVR12) or follow-up Week 24 (SVR24), and HCV RNA undetectable at follow-up Week 12 (SVR12) or follow-up Week 24 (SVR24), respectively.
The EOT for group T2 & PR24 was 26 weeks and for groups T2/PR24 and Pbo/PR24 was 24 weeks.
|
Week 12, 24 after EOT
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów
1 grudnia 2007
Zakończenie podstawowe (Rzeczywisty)
1 czerwca 2008
Ukończenie studiów (Rzeczywisty)
1 maja 2009
Daty rejestracji na studia
Pierwszy przesłany
19 listopada 2007
Pierwszy przesłany, który spełnia kryteria kontroli jakości
19 listopada 2007
Pierwszy wysłany (Oszacować)
20 listopada 2007
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
17 czerwca 2013
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
7 czerwca 2013
Ostatnia weryfikacja
1 czerwca 2013
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby Układu Pokarmowego
- Zakażenia wirusem RNA
- Choroby wirusowe
- Infekcje
- Infekcje przenoszone przez krew
- Choroby zakaźne
- Choroby wątroby
- Infekcje Flaviviridae
- Zapalenie wątroby, wirusowe, ludzkie
- Infekcje enterowirusowe
- Infekcje Picornaviridae
- Zapalenie wątroby, przewlekłe
- Zapalenie wątroby
- Wirusowe Zapalenie Wątroby typu A
- Wirusowe zapalenie wątroby typu C
- Wirusowe zapalenie wątroby typu C, przewlekłe
- Molekularne mechanizmy działania farmakologicznego
- Środki przeciwinfekcyjne
- Środki przeciwwirusowe
- Antymetabolity
- Środki przeciwnowotworowe
- Rybawiryna
- Peginterferon alfa-2a
- Interferon alfa-2
Inne numery identyfikacyjne badania
- CR013513
- VX-950-TiDP24-C209
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Wirusowe zapalenie wątroby typu C, przewlekłe
-
Dokuz Eylul UniversityEge UniversityZakończonyMMP9 | TIMP1 | MMP9-1562 C/T | TIMP1 372 T/CIndyk
-
Johann Wolfgang Goethe University HospitalZakończony
-
Meir Medical CenterZakończonyOpracowanie nowatorskiej techniki pomiaru współczynnika C/D z cyfrowych obrazów dysków optycznych stereo | Odtwarzalność pomiarów C/D wewnątrz obserwatora | Zmienność pomiarów C/D między obserwatorami
-
University College CorkDupont Applied BiosciencesRekrutacyjny
-
University Hospital, GrenobleClinical Investigation Centre for Innovative Technology NetworkZakończony
-
AronPharma Sp. z o. o.Medical University of Warsaw; Medical University of GdanskZakończonyBiodostępność witaminy CPolska
-
University Hospital, CaenZakończonyHemodynamic Monitoring, Positive Inotropic and Vasoactive Drugs During Cardiac Surgery (EMOA) (EMOA)C. Zabieg chirurgiczny; SercowyFrancja
-
University of Sao Paulo General HospitalInCor Heart Institute; Chinese Academy of Medical Sciences, Fuwai Hospital; Beneficência... i inni współpracownicyNieznanyC. Zabieg chirurgiczny; SercowyBrazylia
-
Hongwen JiZakończony
-
Seoul National University HospitalSMG-SNU Boramae Medical CenterZakończonyC. Zabieg chirurgiczny; SercowyRepublika Korei